MYC in pancreatic cancer: Novel mechanistic insights and their translation into therapeutic strategies

Oncogene

Volumn 35, Issue 13, 2016, Pages 1609-1618

  Hessmann, E ^a   Schneider, G ^b   Ellenrieder, V ^a   Siveke, J T ^b,c  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; RNA;

CANCER GROWTH; CARCINOGENESIS; CHROMATIN; DRUG TARGETING; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; IN VIVO STUDY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; REVIEW; RNA PROCESSING; ANIMAL; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOLECULARLY TARGETED THERAPY; ONCOGENE MYC; PANCREATIC NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TRENDS;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 84933576541     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.216     Document Type: Review

References (139)

1. Conacci-Sorrell M, McFerrin L, Eisenman RN. An overview of MYC and its interactome. Cold Spring Harb Perspect Med 2014; 4: a014357.
2. McKeown MR, Bradner JE. Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med 2014; 4: a014266.
3. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008; 8: 976-990.
4. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013; 45: 1134-1140.
5. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013; 45: 1127-1133.
6. Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med 2014; 4: a014241.
7. Huang M, Weiss WA. Neuroblastoma and MYCN. Cold Spring Harb Perspect Med 2013; 3: a014415.
8. Roussel MF, Robinson GW. Role of MYC in medulloblastoma. Cold Spring Harb Perspect Med 2013; 3: a014308.
9. Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med 2014; 4: a014282.
10. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009; 15: 6479-6483.
11. Bachireddy P, Rakhra K, Felsher DW. Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. Clin Exp Immunol 2012; 167: 188-194.
12. Gamberi G, Benassi MS, Böhling T, Ragazzini P, Molendini L, Sollazzo MR et al. Prognostic relevance of C-myc gene expression in giant-cell tumor of bone. J Orthop Res 1998; 16: 1-7.
13. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18: 3004-3016.
14. Skoudy A, Hernández-Munõz I, Navarro P. Pancreatic ductal adenocarcinoma and transcription factors: role of c-Myc. J Gastrointest Cancer 2011; 42: 76-84.
15. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting Cancer Incidence and Deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74: 2913-2921.
16. Soucek L, Whitfield JR, Sodir NM, Massó-Vallés D, Serrano E, Karnezis AN et al. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev 2013; 27: 504-513.
17. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM et al. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455: 679-683.
18. Wells JM, Esni F, Boivin GP, Aronow BJ, Stuart W, Combs C et al. Wnt/betacatenin signaling is required for development of the exocrine pancreas. BMC Dev. Biol. 2007; 7: 4.
19. Stellas D, Szabolcs M, Koul S, Li Z, Polyzos A, Anagnostopoulos C et al. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. J Natl Cancer Inst 2014; 106: dju320.
20. Biankin AV, Waddell N, Kassahn KS, Gingras M, Muthuswamy LB, Johns AL et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012; 491: 399-405.
21. Waddell N, Pajic M, Patch A, Chang DK, Kassahn KS, Bailey P et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518: 495-501.
22. di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 2013; 144: 1220-1229.
23. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415-421.
24. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.
25. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-450.
26. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7: 469-483.
27. Zhou Q, Law AC, Rajagopal J, Anderson WJ, Gray PA, Melton DA. A multipotent progenitor domain guides pancreatic organogenesis. Dev Cell 2007; 13: 103-114.
28. Bonal C, Thorel F, Ait-Lounis A, Reith W, Trumpp A, Herrera PL. Pancreatic inactivation of c-Myc decreases acinar mass and transdifferentiates acinar cells into adipocytes in mice. Gastroenterology 2008; 136: 309-319.
29. Dessimoz J, Bonnard C, Huelsken J, Grapin-Botton A. Pancreas-specific deletion of beta-catenin reveals Wnt-dependent and Wnt-independent functions during development. Curr Biol 2005; 15: 1677-1683.
30. Nakhai H, Siveke JT, Mendoza-Torres L, Schmid RM. Conditional inactivation of Myc impairs development of the exocrine pancreas. Development 2008; 135: 3191-3196.
31. Heiser PW, Lau J, Taketo MM, Herrera PL, Hebrok M. Stabilization of beta-catenin impacts pancreas growth. Development 2006; 133: 2023-2032.
32. Murtaugh LC, Law AC, Dor Y, Melton DA. Beta-catenin is essential for pancreatic acinar but not islet development. Development 2005; 132: 4663-4674.
33. Hermeking H, Rago C, Schuhmacher M, Li Q, Barrett JF, Obaya AJ et al. Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci USA 2000; 97: 2229-2234.
34. Aichler M, Seiler C, Tost M, Siveke J, Mazur PK, Da Silva-Buttkus P et al. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J Pathol 2012; 226: 723-734.
35. Rooman I, Real FX. Pancreatic ductal adenocarcinoma and acinar cells: a matter of differentiation and development Gut 2011; 61: 449-458.
36. Sandgren EP, Quaife CJ, Paulovich AG, Palmiter RD, Brinster RL. Pancreatic tumor pathogenesis reflects the causative genetic lesion. Proc Natl Acad Sci USA 1991; 88: 93-97.
37. Grippo PJ, Sandgren EP. Acinar-to-ductal metaplasia accompanies c-mycinduced exocrine pancreatic cancer progression in transgenic rodents. Int J Cancer 2012; 131: 1243-1248.
38. Lin W, Rajbhandari N, Liu C, Sakamoto K, Zhang Q, Triplett AA et al. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Res 2013; 73: 1821-1830.
39. Sancho R, Gruber R, Gu G, Behrens A. Loss of Fbw7 reprograms adult pancreatic ductal cells into , , and cells. Cell Stem Cell 2014; 15: 139-153.
40. Boj SF, Hwang C, Baker LA, Chio IIC, Engle DD, Corbo V et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 2014; 160: 324-338.
41. Puri S, Folias AE, Hebrok M. Plasticity and dedifferentiation within the pancreas: development, homeostasis, and disease. Cell Stem Cell 2014; 16: 18-31.
42. Mazur PK, Einwächter H, Lee M, Sipos B, Nakhai H, Rad R et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA 2010; 107: 13438-13443.
43. Ischenko I, Petrenko O, Hayman MJ. Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas. Proc Natl Acad Sci USA 2014; 111: 3466-3471.
44. de Alboran IM, O'Hagan RC, Gärtner F, Malynn B, Davidson L, Rickert R et al. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity 2001; 14: 45-55.
45. Politi K, Kljuic A, Szabolcs M, Fisher P, Ludwig T, Efstratiadis A. 'Designer' tumors in mice. Oncogene 2003; 23: 1558-1565.
46. Saborowski M, Saborowski A, Morris JP, Bosbach B, Dow LE, Pelletier J et al. A modular and flexible ESC-based mouse model of pancreatic cancer. Genes Dev 2014; 28: 85-97.
47. Schönhuber N, Seidler B, Schuck K, Veltkamp C, Schachtler C, Zukowska M et al. A next-generation dual-recombinase system for time-and host-specific targeting of pancreatic cancer. Nat Med 2014; 20: 1340-1347.
48. Guccione E, Martinato F, Finocchiaro G, Luzi L, Tizzoni L, Dall' Oli V et al. Mycbinding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol 2006; 8: 764-770.
49. Soucek L, Helmer-Citterich M, Sacco A, Jucker R, Cesareni G, Nasi S. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene 1998; 17: 2463-2472.
50. Soucek L, Jucker R, Panacchia L, Ricordy R, Tatò F, Nasi S. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res 2002; 62: 3507-3510.
51. Soucek L, Nasi S, Evan GI. Omomyc expression in skin prevents Myc-induced papillomatosis. Cell Death Differ 2004; 11: 1038-1045.
52. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008; 22: 2755-2766.
53. Sabò A, Amati B. Genome recognition by MYC. Cold Spring Harb Perspect Med 2014; 4.
54. Elkon R, Zeller KI, Linhart C, Dang CV, Shamir R, Shiloh Y. In silico identification of transcriptional regulators associated with c-Myc. Nucleic Acids Res 2004; 32: 4955-4961.
55. Wirth M, Stojanovic N, Christian J, Paul MC, Stauber RH, Schmid RM et al. MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib. Nucleic Acids Res 2014; 42: 10433-10447.
56. McMahon SB, Wood MA, Cole MD. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol 1999; 20: 556-562.
57. Ullius A, Lüscher-Firzlaff J, Costa IG, Walsemann G, Forst AH, Gusmao EG et al. The interaction of MYC with the trithorax protein ASH2L promotes gene transcription by regulating H3K27 modification. Nucleic Acids Res 2014; 42: 6901-6920.
58. McMahon SB, Van Buskirk HA, Dugan KA, Copeland TD, Cole MD. The novel ATMrelated protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 1998; 94: 363-374.
59. Wang B, Li J, Ye Z, Li Z, Wu X. N-myc downstream regulated gene 1 acts as a tumor suppressor in ovarian cancer. Oncol Rep 2014; 31: 2279-2285.
60. Zhang J, Koenig A, Harrison A, Ugolkov AV, Fernandez-Zapico ME, Couch FJ et al. Mutant K-Ras increases GSK-3 gene expression via an ETS-p300 transcriptional complex in pancreatic cancer. Oncogene 2011; 30: 3705-3715.
61. Schneider G, Krämer OH, Schmid RM, Saur D. Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma. J Gastrointest Cancer 2011; 42: 85-92.
62. Zheng Y, Balasubramanyam K, Cebrat M, Buck D, Guidez F, Zelent A et al. Synthesis and evaluation of a potent and selective cell-permeable p300 histone acetyltransferase inhibitor. J Am Chem Soc 2005; 127: 17182-17183.
63. Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert MA et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol 2010; 17: 471-482.
64. Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB et al. c-Myc regulates transcriptional pause release. Cell 2010; 141: 432-445.
65. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert J, Barsyte-Lovejoy D et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012; 149: 214-231.
66. Bisgrove DA, Mahmoudi T, Henklein P, Verdin E. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc Natl Acad Sci USA 2007; 104: 13690-13695.
67. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O et al. Selective inhibition of BET bromodomains. Nature 2010; 468: 1067-1073.
68. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
69. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-538.
70. Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH et al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res 2013; 19: 6183-6192.
71. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012; 120: 2843-2852.
72. Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MGM, Qi J et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013; 24: 777-790.
73. van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 1989; 56: 673-682.
74. Breuer M, Slebos R, Verbeek S, van Lohuizen M, Wientjens E, Berns A. Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice. Nature 1989; 340: 61-63.
75. Zippo A, De Robertis A, Serafini R, Oliviero S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 2007; 9: 932-944.
76. Xu D, Cobb MG, Gavilano L, Witherspoon SM, Williams D, White CD et al. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine. Cancer Biol Ther 2013; 14: 492-501.
77. Wiese KE, Walz S, Eyss von B, Wolf E, Athineos D, Sansom O et al. The role of MIZ-1 in MYC-dependent tumorigenesis. Cold Spring Harb Perspect Med 2013; 3: a014290.
78. Walz S, Lorenzin F, Morton J, Wiese KE, Eyss von B, Herold S et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature 2014; 511: 483-487.
79. van Riggelen J, Müller J, Otto T, Beuger V, Yetil A, Choi PS et al. The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev 2010; 24: 1281-1294.
80. Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod Pathol 2002; 15: 462-469.
81. Bardeesy N, Aguirre AJ, Chu GC, Cheng K, Lopez LV, Hezel AF et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006; 103: 5947-5952.
82. Birnbaum DJ, Adélaïde J, Mamessier E, Finetti P, Lagarde A, Monges G et al. Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes Cancer 2011; 50: 456-465.
83. La Rosa FA, Pierce JW, Sonenshein GE. Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol Cell Biol 1994; 14: 1039-1044.
84. Lee H, Wu M, La Rosa FA, Duyao MP, Buckler AJ, Sonenshein GE. Role of the Rel-family of transcription factors in the regulation of c-myc gene transcription and apoptosis of WEHI 231 murine B-cells. Curr Top Microbiol Immunol 1995; 194: 247-255.
85. Yochum GS. Multiple Wnt/ß-catenin responsive enhancers align with the MYC promoter through long-range chromatin loops. PLoS ONE 2011; 6: e18966.
86. Bierie B, Moses HL. TGF-beta and cancer. Cytokine Growth Factor Rev 2005; 17: 29-40.
87. Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.
88. Schneider G, Schmid RM. Genetic alterations in pancreatic carcinoma. Mol Cancer 2003; 2: 15.
89. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 2008; 7: 829-840.
90. Buchholz M, Schatz A, Wagner M, Michl P, Linhart T, Adler G et al. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J 2006; 25: 3714-3724.
91. Shaw JP, Utz PJ, Durand DB, Toole JJ, Emmel EA, Crabtree GR. Identification of a putative regulator of early T cell activation genes. Science 1988; 241: 202-205.
92. Singh G, Singh SK, König A, Reutlinger K, Nye MD, Adhikary T et al. Sequential activation of NFAT and c-Myc transcription factors mediates the TGF-beta switch from a suppressor to a promoter of cancer cell proliferation. J Biol Chem 2010; 285: 27241-27250.
93. Koënig A, Linhart T, Schlengemann K, Reutlinger K, Wegele J, Adler G et al. NFATinduced histone acetylation relay switch promotes c-Myc-dependent growth in pancreatic cancer cells. Gastroenterology 2009; 138: 1189-1199.
94. Zadran S, Remacle F, Levine RD. miRNA and mRNA cancer signatures determined by analysis of expression levels in large cohorts of patients. Proc Natl Acad Sci USA 2013; 110: 19160-19165.
95. Palanichamy JK, Rao DS. miRNA dysregulation in cancer: towards a mechanistic understanding. Front Genet 2014; 5: 54.
96. Jackstadt R, Hermeking H. MicroRNAs as regulators and mediators of c-MYC function. Biochim Biophys Acta 2014; 1849: 544-553.
97. He W, Li Y, Chen X, Lu L, Bin Tang, Wang Z et al. miR-494 acts as an antioncogene in gastric carcinoma by targeting c-myc. J Gastroenterol Hepatol 2014; 29: 1427-1434.
98. Cannell IG, Kong YW, Johnston SJ, Chen ML, Collins HM, Dobbyn HC et al. p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. Proc Natl Acad Sci USA 2010; 107: 5375-5380.
99. Cheng C, Hwang C, Corney DC, Flesken-Nikitin A, Jiang L, Oner GM et al. miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment. Cell Rep 2014; 6: 1000-1007.
100. Choi YJ, Lin C, Ho JJ, He X, Okada N, Bu P et al. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat Cell Biol. 2011; 13: 1353-1360.
101. Okada N, Lin C, Ribeiro MC, Biton A, Lai G, He X et al. A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression. Genes Dev 2014; 28: 438-450.
102. Menssen A, Hermeking H. c-MYC and SIRT1 locked in a vicious cycle. Oncotarget 2012; 3: 112-113.
103. Tazawa H, Kagawa S, Fujiwara T. MicroRNAs as potential target gene in cancer gene therapy of gastrointestinal tumors. Expert Opin Biol Ther 2011; 11: 145-155.
104. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008; 105: 13421-13426.
105. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006; 25: 6188-6196.
106. Groisman I, Ivshina M, Marin V, Kennedy NJ, Davis RJ, Richter JD. Control of cellular senescence by CPEB. Genes Dev 2006; 20: 2701-2712.
107. Ogami K, Hosoda N, Funakoshi Y, Hoshino S. Antiproliferative protein Tob directly regulates c-myc proto-oncogene expression through cytoplasmic polyadenylation element-binding protein CPEB. Oncogene 2012; 33: 55-64.
108. Ortiz-Zapater E, Pineda D, Martínez-Bosch N, Fernández-Miranda G, Iglesias M, Alameda F et al. Key contribution of CPEB4-mediated translational control to cancer progression. Nat Med 2011; 18: 83-90.
109. Vervoorts J, Lüscher-Firzlaff J, Lüscher B. The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem 2006; 281: 34725-34729.
110. Cattoretti G. MYC expression and distribution in normal mature lymphoid cells. J Pathol 2012; 229: 430-440.
111. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2007; 8: 83-93.
112. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004; 23: 2116-2125.
113. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates Myc protein stability and activity. Mol Cell 2003; 11: 1177-1188.
114. Gao Y, Lin F, Xu P, Nie J, Chen Z, Su J et al. USP22 is a positive regulator of NFATc2 on promoting IL2 expression. FEBS Lett 2014; 588: 878-883.
115. Peter S, Bultinck J, Myant K, Jaenicke LA, Walz S, Müller J et al. Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase. EMBO Mol Med 2014; 6: 1525-1541.
116. Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L et al. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell 2013; 24: 75-89.
117. Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E et al. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell 2014; 26: 414-427.
118. Yang S, He S, Zhou X, Liu M, Zhu H, Wang Y et al. Suppression of Aurora-A oncogenic potential by c-Myc downregulation. Exp Mol Med 2010; 42: 759-767.
119. Hodges LC, Cook JD, Lobenhofer EK, Li L, Bennett L, Bushel PR et al. Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res 2003; 1: 300-311.
120. Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 2004; 64: 3103-3111.
121. Fukushima N, Sato N, Prasad N, Leach SD, Hruban RH, Goggins M. Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. Oncogene 2004; 23: 9042-9051.
122. Rojanala S, Han H, Munõz RM, Browne W, Nagle R, Hoff Von DD et al. The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther 2004; 3: 451-457.
123. Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop JM. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci USA 2010; 107: 13836-13841.
124. Cermelli S, Jang IS, Bernard B, Grandori C. Synthetic lethal screens as a means to understand and treat MYC-driven cancers. Cold Spring Harb Perspect Med 2014; 4:: pii: a014209.
125. Liu L, Ulbrich J, Müller J, Wüstefeld T, Aeberhard L, Kress TR et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 2012; 483: 608-612.
126. Lüscher B, Kuenzel EA, Krebs EG, Eisenman RN. Myc oncoproteins are phosphorylated by casein kinase II. EMBO J 1989; 8: 1111-1119.
127. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 2000; 20: 2423-2435.
128. Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M et al. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell 2006; 21: 509-519.
129. Henriksson M, Bakardjiev A, Klein G, Lüscher B. Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene 1993; 8: 3199-3209.
130. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000; 14: 2501-2514.
131. Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther 2011; 12: 598-609.
132. Cowling VH, Cole MD. Mechanism of transcriptional activation by the Myc oncoproteins. Semin Cancer Biol 2006; 16: 242-252.
133. Chang DK, Grimmond SM, Biankin AV. Pancreatic cancer genomics. Curr Opin Genet Dev 2014; 24: 74-81.
134. Gurda GT, Crozier SJ, Ji B, Ernst SA, Logsdon CD, Rothermel BA et al. Regulator of calcineurin 1 controls growth plasticity of adult pancreas. Gastroenterology 2010; 139: 609-619.
135. Singh SK, Baumgart S, Singh G, König AO, Reutlinger K, Hofbauer LC et al. Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid. J Biol Chem 2011; 286: 28761-28771.
136. Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 2010; 62: 1137-1141.
137. Hamacher R, Saur D, Fritsch R, Reichert M, Schmid RM, Schneider G. Casein kinase II inhibition induces apoptosis in pancreatic cancer cells. Oncol Rep 2007; 18: 695-701.
138. Nam S, Wen W, Schroeder A, Herrmann A, Yu H, Cheng X et al. Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutivelyactivated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Mol Oncol 2012; 7: 369-378.
139. Sahai V, Kumar K, Knab LM, Chow CR, Raza SS, Bentrem DJ et al. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Mol Cancer Ther 2014; 13: 1907-1917.